April 11, 2022 -- Oxford BioTherapeutics will present preliminary clinical data from its ongoing expansion phase I trial of its experimental CD205-directed antibody drug conjugate (ADC), OBT076, on April 11 at the American Association of Cancer Research (AACR) Annual Meeting.
Oxford's summary of the presentation states that OBT076 (NCT04064359) (2-5 cycles) in combination with a checkpoint inhibitor (CPI) (1-2 cycles) showed near complete responses in low programmed cell death ligand 1 refractory solid tumor patients. Patients treated with the combination also showed tumor shrinkage, immune response, and a decrease of metastasis. The combination synergizes through a potentially novel mechanism: drug-induced depletion of CD205+ immuno-suppressive cells and subsequent T-cell activation.
Based on this preliminary data, Oxford will advance OBT076 into single agent and combination trials (with CPIs) in both checkpoint-naïve and resistant patients, according to the summary.
Copyright © 2022 scienceboard.net